WO2003000842A3 - Nouvelles proteines et acides nucleiques codant pour de telles proteines - Google Patents

Nouvelles proteines et acides nucleiques codant pour de telles proteines Download PDF

Info

Publication number
WO2003000842A3
WO2003000842A3 PCT/US2002/017443 US0217443W WO03000842A3 WO 2003000842 A3 WO2003000842 A3 WO 2003000842A3 US 0217443 W US0217443 W US 0217443W WO 03000842 A3 WO03000842 A3 WO 03000842A3
Authority
WO
WIPO (PCT)
Prior art keywords
small molecule
molecule target
nucleic acids
acids encoding
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/017443
Other languages
English (en)
Other versions
WO2003000842A2 (fr
Inventor
Michele L Agee
David W Anderson
Constance Berghs
Stacie J Casman
Elina Catterton
Vincent A Dipippo
Shlomit R Edinger
Andrew Eisen
Karen Ellerman
Esha A Gangolli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CuraGen Corp
Original Assignee
CuraGen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CuraGen Corp filed Critical CuraGen Corp
Priority to JP2003507229A priority Critical patent/JP2005518185A/ja
Priority to EP02765778A priority patent/EP1578905A2/fr
Priority to CA002447941A priority patent/CA2447941A1/fr
Publication of WO2003000842A2 publication Critical patent/WO2003000842A2/fr
Anticipated expiration legal-status Critical
Publication of WO2003000842A3 publication Critical patent/WO2003000842A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne de nouveaux polynucléotides isolés et des polypeptides cibles à petites molécules codés par les polynucléotides. L'invention concerne également des anticorps de liaison immunospécifique au polypeptide cible à petites molécules ou tout dérivé, variant, mutant ou fragment dudit polypeptide, polynucléotide ou anticorps ainsi que des procédés dans lesquels le polypeptide cible, polynucléotide et anticorps sont utilisés dans la détection et le traitement d'une large gamme de conditions pathologiques. Plus précisément, la présente invention décrit des procédés d'utilisation de protéines exprimées de manière recombinante et/ou endogène dans divers procédés permettant l'identification d'anticorps thérapeutiques et de petites molécules thérapeutiques associés aux maladies.
PCT/US2002/017443 2001-06-04 2002-06-04 Nouvelles proteines et acides nucleiques codant pour de telles proteines Ceased WO2003000842A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2003507229A JP2005518185A (ja) 2001-06-04 2002-06-04 新規タンパク質およびそれをコード化する核酸
EP02765778A EP1578905A2 (fr) 2001-06-04 2002-06-04 Nouvelles proteines et acides nucleiques codant pour de telles proteines
CA002447941A CA2447941A1 (fr) 2001-06-04 2002-06-04 Nouvelles proteines et acides nucleiques codant pour de telles proteines

Applications Claiming Priority (72)

Application Number Priority Date Filing Date Title
US29560701P 2001-06-04 2001-06-04
US29566101P 2001-06-04 2001-06-04
US60/295,607 2001-06-04
US60/295,661 2001-06-04
US29641801P 2001-06-06 2001-06-06
US29640401P 2001-06-06 2001-06-06
US60/296,418 2001-06-06
US60/296,404 2001-06-06
US29657501P 2001-06-07 2001-06-07
US60/296,575 2001-06-07
US29741401P 2001-06-11 2001-06-11
US60/297,414 2001-06-11
US29756701P 2001-06-12 2001-06-12
US29757301P 2001-06-12 2001-06-12
US60/297,567 2001-06-12
US60/295,573 2001-06-12
US29828501P 2001-06-14 2001-06-14
US60/298,285 2001-06-14
US29852801P 2001-06-15 2001-06-15
US60/298,528 2001-06-15
US29913301P 2001-06-18 2001-06-18
US60/299,133 2001-06-18
US29923001P 2001-06-19 2001-06-19
US60/299,230 2001-06-19
US29994901P 2001-06-21 2001-06-21
US60/299,949 2001-06-21
US30017701P 2001-06-22 2001-06-22
US60/300,177 2001-06-22
US30088301P 2001-06-26 2001-06-26
US60/300,883 2001-06-26
US30153001P 2001-06-28 2001-06-28
US30155001P 2001-06-28 2001-06-28
US60/301,550 2001-06-28
US60/301,530 2001-06-28
US30295101P 2001-07-03 2001-07-03
US60/302,951 2001-07-03
US30889001P 2001-07-31 2001-07-31
US60/308,890 2001-07-31
US32229701P 2001-09-14 2001-09-14
US60/322,297 2001-09-14
US32466901P 2001-09-25 2001-09-25
US60/324,669 2001-09-25
US33747701P 2001-12-03 2001-12-03
US60/337,477 2001-12-03
US34156201P 2001-12-14 2001-12-14
US60/341,562 2001-12-14
US35912202P 2002-02-21 2002-02-21
US35865602P 2002-02-21 2002-02-21
US60/359,122 2002-02-21
US60/358,656 2002-02-21
US35912102P 2002-02-22 2002-02-22
US35897802P 2002-02-22 2002-02-22
US35903502P 2002-02-22 2002-02-22
US35903402P 2002-02-22 2002-02-22
US60/359,035 2002-02-22
US60/359,121 2002-02-22
US60/358,978 2002-02-22
US60/359,034 2002-02-22
US35996402P 2002-02-27 2002-02-27
US60/359,964 2002-02-27
US36085802P 2002-03-01 2002-03-01
US60/360,858 2002-03-01
US36343002P 2002-03-12 2002-03-12
US36367602P 2002-03-12 2002-03-12
US60/363,676 2002-03-12
US60/363,430 2002-03-12
US37134602P 2002-04-10 2002-04-10
US60/371,346 2002-04-10
US37944402P 2002-05-10 2002-05-10
US60/379,444 2002-05-10
US16061902A 2002-06-03 2002-06-03
US10/160,619 2002-06-03

Publications (2)

Publication Number Publication Date
WO2003000842A2 WO2003000842A2 (fr) 2003-01-03
WO2003000842A3 true WO2003000842A3 (fr) 2005-11-03

Family

ID=34744079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/017443 Ceased WO2003000842A2 (fr) 2001-06-04 2002-06-04 Nouvelles proteines et acides nucleiques codant pour de telles proteines

Country Status (2)

Country Link
JP (1) JP2005518185A (fr)
WO (1) WO2003000842A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056138B2 (en) 2002-03-01 2015-06-16 Bracco Suisse Sa Multivalent constructs for therapeutic and diagnostic applications
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041494B2 (en) * 2000-11-15 2006-05-09 Icagen, Inc. DNA encoding Slo2 and Slo4, potassium channel
US6815181B2 (en) * 2001-07-09 2004-11-09 Applera Corporation Nucleic acid molecules encoding human secreted hemopexin-related proteins
ES2396368T3 (es) * 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
EP2478912B1 (fr) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Conjugués d'auristatin avec des anticorps dirigés contre le HER2 ou le CD22 et leur usage thérapeutique
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JP2006217859A (ja) * 2005-02-10 2006-08-24 Japan Health Science Foundation アルツハイマー病の治療薬または予防薬のスクリーニング方法、およびアルツハイマー病を診断する方法、アルツハイマー病発症の危険度を予測する方法
EP1849877A1 (fr) * 2006-04-24 2007-10-31 Erasmus University Medical Center Rotterdam Histoire réplicative de sous-ensembles de lymphocytes T et B
DE102007017433A1 (de) * 2007-04-03 2008-10-09 Eberhard-Karls-Universität Tübingen Universitätsklinikum PIKfyve als pharmakologisches Target zur Behandlung von glucosestoffwechselassoziierten Krankheiten
JP2013504585A (ja) 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
CA2799540A1 (fr) 2010-06-08 2011-12-15 Genentech, Inc. Anticorps et conjugues modifies par la cysteine
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
US9598733B2 (en) 2011-02-17 2017-03-21 The Trustees Of Columbia University In The City Of New York Methods for identifying subjects with a genetic risk for developing IgA nephropathy
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
JP5864918B2 (ja) * 2011-07-06 2016-02-17 国立大学法人東北大学 オートタキシンアイソフォーム特異的抗体および検出方法
BR112014009050B1 (pt) 2011-10-14 2022-06-21 Medimmune Limited Conjugado anticorpo-fármaco de pirrolbenzodiazepinas, composição farmacêutica que compreende o mesmo, bem como compostos de pirrolbenzodiazepinas
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
RS57694B1 (sr) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pirolobenzodiazepin - anti-psma konjugati antitela
EP2906296B1 (fr) 2012-10-12 2018-03-21 ADC Therapeutics SA Conjugués anticorps - pyrrolobenzodiazépine
EP2906297B1 (fr) 2012-10-12 2017-12-06 ADC Therapeutics SA Conjugués anticorps - pyrrolobenzodiazépine
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
HRP20182129T1 (hr) 2012-10-12 2019-02-08 Adc Therapeutics Sa Konjugati protutijelo - pirolobenzodiazepin
JP6392765B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
TWI680766B (zh) 2013-03-13 2020-01-01 英商梅迪繆思有限公司 吡咯并苯并二氮呯及其共軛物
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
AU2014229529B2 (en) 2013-03-13 2018-02-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10202647B2 (en) 2013-04-12 2019-02-12 The Trustees Of Columbia University In The City Of New York Mutations in DSTYK cause dominant urinary tract malformations
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052535A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
EP3054983B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépines
WO2015052534A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
WO2015095227A2 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
JP6671292B2 (ja) 2013-12-16 2020-03-25 ジェネンテック， インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
EP3082876B1 (fr) 2013-12-16 2018-01-17 Genentech, Inc. Composés conjugués anticorps-médicament dimérique à base de 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
EP3193940A1 (fr) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
WO2016040825A1 (fr) 2014-09-12 2016-03-17 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN107073136A (zh) 2014-09-17 2017-08-18 健泰科生物技术公司 吡咯并苯并二氮杂卓及其抗体二硫化物偶联物
SG11201703528YA (en) * 2014-11-03 2017-05-30 Univ Nanyang Tech A recombinant expression system that senses pathogenic microorganisms
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
AU2015358532C1 (en) 2014-12-03 2020-10-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
CR20180243A (es) 2015-10-02 2018-07-31 Genentech Inc Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
EP3365025B1 (fr) 2015-10-20 2020-07-15 Genentech, Inc. Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
EP3465221B1 (fr) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Procédé bioanalytique pour la caractérisation de conjugués anticorps-médicament spécifiques d'un site
WO2017214024A1 (fr) 2016-06-06 2017-12-14 Genentech, Inc. Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
CN109689111B (zh) 2016-08-11 2024-04-05 基因泰克公司 吡咯并苯并二氮杂䓬前药及其抗体缀合物
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
CN110582505B (zh) 2017-04-18 2021-04-02 免疫医疗有限公司 吡咯并苯并二氮杂*缀合物
WO2018193102A1 (fr) 2017-04-20 2018-10-25 Adc Therapeutics Sa Polythérapie avec un conjugué anticorps anti-axl-médicament
CA3064804A1 (fr) 2017-06-14 2018-12-20 Adc Therapeutics Sa Regimes posologiques pour l'administration d'un cam anti-cd19
KR102270107B1 (ko) 2017-08-18 2021-06-30 메디뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
EP3684773B1 (fr) 2017-09-20 2026-04-29 pH Pharma Co., Ltd. Analogues de thailanstatine
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP7708662B2 (ja) 2018-10-24 2025-07-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
CN113631560B (zh) 2019-03-15 2025-02-18 麦迪穆有限责任公司 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
EP4426727A2 (fr) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Conjugaison spécifique d'un anticorps
WO2024138128A2 (fr) 2022-12-23 2024-06-27 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations
KR20260012304A (ko) 2023-04-17 2026-01-26 피크 바이오, 인크. 항체 및 항체-약물 접합체 및 사용 방법 및 합성 공정 및 중간체
WO2026006689A2 (fr) 2024-06-28 2026-01-02 Firefly Bio, Inc. Conjugués anticorps-dégradeur de bcl-xl et leurs utilisations
WO2026006688A2 (fr) 2024-06-28 2026-01-02 Firefly Bio, Inc. Conjugués d'anticorps de dégradation et leurs utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. BIOPHYS. ACTA 1519, vol. 1-2, 2001, pages 117 - 121 *
DATABASE GENBANK [online] VIGETTI D. ET AL: "Molecular cloning of mouse allantoicase cDNA", XP002991050, Database accession no. (AF278712) *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056138B2 (en) 2002-03-01 2015-06-16 Bracco Suisse Sa Multivalent constructs for therapeutic and diagnostic applications
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9381258B2 (en) 2002-03-01 2016-07-05 Bracco Suisse S.A. Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
JP2005518185A (ja) 2005-06-23
WO2003000842A2 (fr) 2003-01-03

Similar Documents

Publication Publication Date Title
WO2003000842A3 (fr) Nouvelles proteines et acides nucleiques codant pour de telles proteines
WO2002081498A3 (fr) Nouvelles proteines et acides nucleiques codant pour ces proteines
WO2003010327A3 (fr) Nouvelles proteines et acides nucleiques les codant
WO2003040325A3 (fr) Nouvelles proteines et acides nucleiques codant ces proteines
WO2001036645A3 (fr) Nouveaux polypeptides et acides nucleiques codant les memes
WO2002072757A3 (fr) Proteines et acides nucleiques codant pour ces proteines
WO2000053742A3 (fr) Polynucleotides et proteines codees par ceux-ci
WO2001049729A3 (fr) Nouveaux polypeptides et acides nucleiques codant ceux-ci
WO2003083046A3 (fr) Nouvelles proteines et acides nucleiques codant pour de telles proteines
WO2003023001A3 (fr) Nouvelles proteines et acides nucleiques codant ces proteines
WO2003029424A3 (fr) Nouvelle proteines et acides nucleiques codant celles-ci
WO2003064628A3 (fr) Mandrin a vide faisant intervenir un materiau fritte et procede de fabrication
WO2001074856A3 (fr) Polypeptides de type wnt-7b et acides nucleiques codant pour ceux-ci
WO2002002625A3 (fr) Nouveaux facteurs de croissance des fibroblastes et acides nucleiques codant pour ces memes facteurs
WO2003102159A3 (fr) Nouvelles proteines et nouveaux acides nucleiques codant pour ces proteines
WO2001062928A3 (fr) Polypeptides et acides nucleiques codant pour
WO2001070978A3 (fr) Nouveaux polypeptides et acides nucleiques codant ces polypeptides
WO2003025147A3 (fr) Nouveaux polynucleotides et proteines codees par ceux-ci
WO2000061754A3 (fr) Nouvelles proteines humaines et polypeptides codant pour ces proteines
WO2001061009A3 (fr) Nouveaux polypeptides et acides nucleiques les codant
WO2001044473A3 (fr) Polypeptides et acides nucleiques codant pour ces polypeptides
WO2004048512A3 (fr) Nouvelles proteines et acides nucleiques codant pour ces proteines
WO2001036638A3 (fr) Nouveaux polypeptides et acides nucleiques codant pour ces polypeptides
WO2003057854A3 (fr) Nouvelles proteines et acides nucleiques codant ces dernieres
WO2003076642A3 (fr) Nouvelles proteines et acides nucleiques codant ces proteines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US US US US US US US US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002329178

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2447941

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003507229

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002765778

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004104635

Country of ref document: RU

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002765778

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002765778

Country of ref document: EP